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Simple Summary: Alteration of metabolism, including glycolysis and glutaminolysis in malignant
tumours, has become a hallmark of cancer and related biological aggressiveness. The metabolic
signature of each cancer has been actively investigated for potential new drug development. Of
the metabolic imaging biomarkers, F-18 fluorodeoxyglucose (FDG) and C-11 methionine positron
emission tomography/computed tomography (PET/CT) are widely studied to evaluate the degree of
glucose metabolism and amino acid metabolism, respectively. In this prospective study, we found that
both F-18 FDG and C-11 methionine uptakes on PET/CT were heterogeneous in renal cell carcinomas,
and increased uptake was associated with higher grades of both radiotracers. Additionally, metabolic
tumour volume on F-18 FDG PET/CT but not C-11 methionine PET/CT was significant in predicting
advanced-stage renal cell carcinoma. These metabolic features derived with PET/CT may help in the
development of new drugs targeting glucose and amino acid metabolic pathways.
Abstract: We evaluated the value of F-18 fluorodeoxyglucose (FDG) and C-11 methionine positron
emission tomography/computed tomography (PET/CT) to predict high-Fuhrman grade and advanced-
stage tumours in patients with renal cell carcinoma (RCC). Forty patients with RCC underwent
F-18 FDG and C-11 methionine PET/CT between September 2016 and September 2018. They were
classified into limited (stages I and II, n = 15) or advanced stages (stages III and IV, n = 25) according
to pathological staging. Logistic regressions were used to predict the advanced stage using various
parameters, including maximum standardised uptake value (SUVmax) and metabolic tumour volume
(MTV). Receiver operating characteristic analyses were performed to predict high-grade tumours
(Fuhrman 3 and 4). On univariate analysis, tumour size, SUVmax and MTV of F-18 FDG and C-11
methionine, and Fuhrman grades were significant predictors for the advanced stage. On multivariate
analysis, F-18 FDG MTV > 21.3 cm3 was the most significant predictor (p < 0.001). The area under
the curve for predicting high-grade tumours was 0.830 for F-18 FDG (p < 0.001) and 0.726 for C-11
methionine PET/CT (p = 0.014). In conclusion, glycolysis on F-18 FDG PET/CT and amino acid
metabolism on C-11 methionine PET/CT were variable but increased in high-grade RCCs. Increased
MTV on F-18 FDG PET/CT is a powerful predictor of advanced-stage tumours.
Keywords: F-18 fluorodeoxyglucose; C-11 methionine; positron emission tomography; renal
cell carcinoma
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1. Introduction
Renal cell carcinoma (RCC) is the sixth-most common cancer in males and the eighth-
most common cancer in women. It is the most lethal urological cancer, with a mortality
rate of 25% [1]. Accurate staging of RCC is of utmost importance because the selection
of different therapeutic strategies, such as surgery or systemic treatment, depends on the
detection of metastatic lesions at a single site or several sites [2]. Preoperative prediction of
biologically aggressive RCCs is limited owing to the lack of reliable clinical or radiological
criteria. Although multigene assays have been increasingly used for improved prognosti-
cation, non-invasive imaging biomarkers can help identify patients with a higher risk of
advanced disease for appropriate treatment-related decision-making at staging [3].
Alteration of metabolism is a hallmark of cancer and has various biological impli-
cations. For example, aerobic glycolysis is promoted by the activation of many growth
factor signalling pathways, such as EGFR, glutaminolysis to protect cancer cells from ox-
idative stress, and tryptophan metabolism to generate immunosuppressive compounds [4].
Investigation of metabolic signatures in each cancer could be useful in developing new
drugs targeting specific metabolic pathways. Of the metabolic imaging biomarkers, F-
18 fluorodeoxyglucose (FDG) and C-11 methionine (MET) positron emission tomogra-
phy/computed tomography (PET/CT) are widely used to evaluate the degree of glucose
metabolism and amino acid metabolism, respectively [5]. To date, a significant portion of
RCCs is known for low F-18 FDG uptake due to low glycolysis [6]. A meta-analysis on the
detection of RCC using F-18 FDG PET reported a pooled sensitivity of 62% (95% confidence
interval (CI): 49–74%) [7]. Importantly, RCCs with a high F-18 FDG uptake have been asso-
ciated with tumour aggressiveness, such as Fuhrman grade [2,8–10], phosphorylated Akt
and S6 kinase [11], and metastatic lesions [2,12,13]. The roles of metabolic tumour volume
(MTV) in glycolysis on F-18 FDG PET/CT in primary RCC have not been evaluated.
Since cellular proliferation is associated with increased protein synthesis, radiolabeled
amino acids, including C-11 MET, are used to evaluate various malignant tumours [12–19].
Other than protein synthesis, transamination, ATP generation, nucleotide synthesis, and
methylation reactions are closely related to amino acids, including MET [20]. C-11 MET is
the most-used radiotracer for detecting and grading cerebral gliomas with high sensitivity,
even in non-glycolytic, low-grade tumours [21,22]. Unlike F-18 FDG, it has minimal
excretion through the kidneys, which may increase its ability to detect RCCs. Although a
small pilot study suggested the potential value of C-11 MET for detecting primary tumours
and metastases in patients with RCC [23], further research is limited.
This prospective study aimed to assess the effects of glycolysis on F-18 FDG and amino
acid metabolism on C-11 MET PET/CT to predict high Fuhrman grade and advanced-stage
tumours in patients with RCC.
2. Results
2.1. Patient Characteristics
Altogether, 40 patients (21 males and 19 females) were included in this study. The
mean age was 59.6 ± 12.5 years, and the mean tumour size was 8.2 ± 2.4 cm. Among the
40 patients, 5 (12.5%) had stage I tumours, 10 (25.0%) had stage II tumours, 16 (40.0%)
had stage III tumours, and 9 (22.5%) had stage IV tumours. Fuhrman nuclear grades
were low (grades 1 and 2) in 12 patients and high (grades 3 and 4) in 28 patients. On
visual analysis, F-18 FDG uptake was positive in 30 tumours, and C-11 MET uptake was
positive in 24 tumours (75.0% vs. 60.0%, p = 0.109). Inter-observer agreement between
two interpreters was good in both F-18 FDG (kappa: 0.678, 95% CI 0.453–0.903) and C-
11 MET (kappa: 0.652, 95% CI 0.420–0.884) PET/CT. Patient characteristics according
to the American Joint Committee on Cancer (AJCC) stages are summarised in Table 1.
Characteristics of individual patients can be found in Table S1.
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Male, n (%) 3 (60.0%) 4 (40.0%) 11 (68.8%) 3 (33.3%)
Female, n (%) 2 (40.0%) 6 (60.0%) 5 (31.3%) 6 (66.7%)















Clear cell type, n (%) 3 (60.0%) 8 (80.0%) 14 (87.5%) 9 (100.0%)
Chromophobe type, n (%) 1 (20.0%) 2 (20.0%) 1 (6.3%) 0 (0.0%)




































Grade 1, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Grade 2, n (%) 2 (40.0%) 6 (60.0%) 1 (6.3%) 3 (33.3%)
Grade 3, n (%) 2 (40.0%) 4 (40.0%) 11 (68.8%) 5 (55.6%)
Grade 4, n (%) 1 (20.0%) 0 (0.0%) 4 (25.0%) 1 (11.1%)
AJCC, American Joint Committee on Cancer; FDG, fluorodeoxyglucose; MET, methionine; MTV, metabolic tumour
volume; PET/CT, positron emission tomography/computed tomography; Q1, 25th percentile; Q3, 75th percentile;
SUVmax, maximum standardised uptake value.
2.2. Logistic Regression Analysis for the Prediction of Advanced-Stage Disease
The limited stage disease was observed in 15 patients, while 25 patients had advanced-
stage disease. Simple logistic regression results showed tumour size, F-18 FDG SUVmax,
F-18 FDG MTV, C-11 MET SUVmax, C-11 MET MTV, and Fuhrman nuclear grades as
significant predictors for advanced-stage disease. Among these factors, F-18 FDG MTV was
the only significant predictor of advanced-stage disease in the stepwise logistic regression
analysis (Table 2). A primary tumour with an F-18 FDG MTV cut-off > 21.3 cm3 was a
significant predictor of advanced-stage disease (odds ratio, 102.67; 95% CI, 9.69–1087.62;
p < 0.001). Representative cases are shown in Figures 1 and 2, respectively.
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Table 2. Logistic regression results of renal cell carcinoma patients to predict advanced-stage disease
(III and IV).
Characteristics
Univariate Analysis Multivariate Analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Sex (male vs. female) 1.46(0.40–5.26) 0.568
Age (years) 1.05(0.99–1.11) 0.121
Tumour size (cm) 1.47(1.03–2.09) 0.033 *
F-18 FDG PET/CT
SUVmax (≤4.6 vs. >4.6)
26.00
(4.38–154.53) <0.001 *




SUVmax (≤5.0 vs. >5.0)
8.71
(2.01–37.76) 0.004 *





Only one predictor was selected using the stepwise method. CI, confidence interval; FDG, fluorodeoxyglu-
cose; MET, methionine; MTV, metabolic tumour volume; OR, odds ratio; PET/CT, positron emission to-
mography/computed tomography; SD, standard deviation; SUVmax, maximum standardised uptake value.
* p-value < 0.05 was considered significant.
Figure 1. RCC with low MTV. A 56-year-old male had a renal mass (arrowhead) with low F-18
FDG uptake ((A) SUVmax: 2.16, MTV: 0.0 cm3) and low C-11 MET uptake ((B) SUVmax: 1.49, MTV:
1.38 cm3). A 7.7-cm-sized Fuhrman grade 2 clear cell carcinoma was reported after surgery. The
pathological stage was stage II (T2a N0 M0). RCC, renal cell carcinoma; FDG, fluorodeoxyglucose;
MET, methionine; SUVmax, maximum standardised uptake value; MTV, metabolic tumour volume.
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Figure 2. RCC with high MTV. A 66-year-old female had a renal mass (black arrowhead) with high F-18 FDG uptake
((A) SUVmax : 7.64, MTV: 515.38 cm3) and high C-11 MET uptake ((B) SUVmax: 9.93, MTV: 424.01 cm3). (C) Bone metastases
(white arrowhead) were also noted on F-18 FDG and C-11 MET PET/CT but were not well-noted on the whole-body bone
scan. A 13.0-cm-sized Fuhrman grade 3 clear cell carcinoma was reported after surgery, and the pathological stage was
IV (T4 N1 M1). RCC, renal cell carcinoma; FDG, fluorodeoxyglucose; MET, methionine; SUVmax, maximum standardised
uptake value; MTV, metabolic tumour volume.
2.3. Comparison of F-18 FDG and C-11 MET Uptake in the Primary Tumour and
Histopathological Findings
There was a moderate correlation between the SUVmax of F-18 FDG and C-11 MET
PET/CT (r = 0.63, p < 0.001, Figure 3) for primary tumours. Tumours with high Fuhrman
grades showed higher SUVmax than low-grade tumours on both F-18 FDG (4.1 ± 2.1 vs.
9.2 ± 6.0, p = 0.001) and C-11 MET PET/CT (4.4 ± 2.5 vs. 6.7 ± 2.5, p = 0.024) (Figure 4). The
mean F-18 FDG SUVmax of high-grade tumours was 124% higher than that of low-grade
tumours, while the mean C-11 MET SUVmax of high-grade tumours was only 52% higher
than that of low-grade tumours. In the receiver operating characteristic (ROC) analysis
for grading, the area under the curve (AUC) was 0.830 for F-18 FDG SUVmax (cut-off > 6.0,
p < 0.001), while it was 0.726 for C-11 MET SUVmax (cut-off > 4.3, p = 0.014). The AUC of
F-18 FDG SUVmax was slightly greater than that of C-11 MET SUVmax, but the difference
was not statistically significant (p = 0.262). In contrast to the SUVmax of F-18 FDG and C-11
MET, tumour size was not correlated with Fuhrman grade (p = 0.315). In addition, the
SUVmax of both F-18 FDG and C-11 MET was not significantly correlated with tumour size
(p = 0.688 and p = 0.794, respectively).
2.4. Comparison of Detection of Extra-Renal Metastases between Conventional Imaging and PET/CT
Three patients had regional lymph node metastases on pathological examination,
which could be detected on abdominal CT, F-18 FDG PET/CT, and C-11 MET PET/CT.
Nine patients had distant metastases (six with lung metastases, two with bone metastases,
and one with lung and bone metastases). All lung metastases were detected on chest
CT, F-18 FDG PET/CT, and C-11 MET PET/CT. Bone metastases in three patients were
negative or equivocal on conventional imaging but showed positive uptake on both F-18
FDG and C-11 MET PET/CT.
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Figure 3. Correlation between F-18 FDG and C-11 MET uptake in RCC. There was a moderate
correlation between the SUVmax of F-18 FDG and C-11 MET PET/CT (r = 0.63, p < 0.001). RCC,
renal cell carcinoma; FDG, fluorodeoxyglucose; MET, methionine; SUVmax, maximum standardised
uptake value.
Figure 4. Comparison of F-18 FDG (A) and C-11 MET (B) uptake of low-grade (grades 1 and 2) and high-grade (grades 3
and 4) RCCs. Tumours with high Fuhrman grades showed higher SUVmax than low-grade tumours on both F-18 FDG ((A)
4.1 ± 2.1 vs. 9.2 ± 6.0, p = 0.001) and C-11 MET PET/CT ((B) 4.4 ± 2.5 vs. 6.7 ± 2.5, p = 0.024)). RCC, renal cell carcinoma;
FDG, fluorodeoxyglucose; MET, methionine; SUVmax, maximum standardised uptake value
3. Discussion
Both F-18 FDG uptake, an imaging surrogate for glycolysis, and C-11 MET uptake
for amino acid metabolism on PET/CT generally reflect rapid proliferation and poor
differentiation in cancer [24–26]. A good correlation between F-18 FDG and C-11 MET
uptake has been reported in cerebral gliomas [27]. In this study, we also found a moderate
correlation between F-18 FDG and C-11 MET uptake in primary RCC. Both metabolic
radiotracer uptakes were higher in high-grade tumours than in low-grade tumours, and the
difference in uptake between the high-grade and low-grade tumours was more prominent
with F-18 FDG. Regardless, ROC analysis showed that both F-18 FDG SUVmax and C-
11 MET SUVmax were useful for predicting high-grade tumours (AUC: 0.830 vs. 0.726,
p = 0.262). In contrast, tumour size, a component of T staging, showed no significant
correlation with Fuhrman grade. Thus, metabolic parameters, such as F-18 FDG uptake or
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C-11 MET, seemed more important than tumour size in reflecting the biological behaviour
of RCCs.
In aggressive tumours, an altered pattern of glucose metabolism is observed, generally
called “the Warburg effect” [28]. While upregulation of genes related to glucose metabolism
induces aerobic glycolysis in tumours with sufficient oxygen levels for proliferation, it is an
inefficient way to generate adenosine triphosphate than oxidative phosphorylation [29,30].
This altered metabolism requires more glucose; therefore, cancer cells usually upregulate
glucose transporters [31]. In RCCs, aggressive tumours are known to show a metabolic shift
in which there is downregulation of the TCA cycle genes, decreased levels of AMPK and
PTEN protein, upregulation of the pentose phosphate pathway, and glutamine transporter
genes, and increased enzyme levels for lipid synthesis [32]. In our study, RCCs showed a
wide range of F-18 FDG uptake in the primary tumours, and high F-18 FDG uptake was
associated with high Fuhrman grades. It seems that the known metabolic shift noted in
aggressive RCCs shares metabolic changes in tumours of the Warburg phenotype. Further
studies are needed to determine whether increased glycolysis on F-18 FDG PET/CT is
reflective of the known metabolic signatures in aggressive RCC.
In addition to glycolysis, glutaminolysis plays an essential role in the growth of cancer
cells [33]. In RCC, glutamine is an important source of fatty acids by reductive carboxy-
lation [34,35] and nucleotide biosynthesis [36]. Despite its importance, no radiolabeled
glutamine is available in clinical practice. Instead, radiolabeled essential amino acids
are currently used in patients, and C-11 MET is one of the most commonly used amino
acid-derived radiotracers. Methylthioadenosine phosphorylase (MTAP), a key enzyme
in the methionine salvage pathway, is lost in almost all cancers. Accordingly, cancer cells
show increased MET levels for survival and growth [37]. In RCCs, alterations in leucine
and tryptophan transport by large amino acid transporters have been reported [4,38].
Since MET shares the same transporter system with leucine or tryptophan [39], C-11 MET
PET/CT is a potential candidate for evaluating amino acid metabolism in RCCs. In this
study, we found variable C-11 MET uptake in RCCs, in which increased C-11 MET uptake
was correlated with high grade (AUC of 0.726 with MET SUVmax cut-off > 4.3). By cor-
relating MET SUVmax to MTAP expression in RCCs, C-11 MET PET/CT can be used to
non-invasively select patients with decreased MET salvage pathways in vivo.
Fuhrman’s grade is a well-known predictor of aggressive RCC behaviour [40–42].
However, non-invasive preoperative predictors for the advanced-stage disease are limited.
In the present prospective study, we included clinicopathologic and imaging parameters of
F-18 FDG and C-11 MET PET/CT to predict advanced-stage disease according to AJCC
(pathological TNM stages III and IV). In the univariate analysis, tumour size, F-18 FDG
SUVmax, F-18 FDG MTV, C-11 MET SUVmax, C-11 MET MTV, and Fuhrman grade were pre-
dictive factors. Among these, F-18 FDG MTV was the only independent factor statistically
significant in the multivariate analysis. With a cut-off MTV value > 21.3 cm3, the advanced-
stage disease could be predicted with an odds ratio of 102.67 (95% CI: 9.69–1087.62).
Therefore, patients with high glycolytic tumour volumes should be thoroughly evaluated
for potential advanced-stage disease.
The detection sensitivity of F-18 FDG PET/CT for primary tumours is different from
its sensitivity to extra-renal metastases. For primary tumours, studies have shown a
sensitivity of 47–94% for F-18 FDG PET [43–45]. In this study, we also found a moderate
sensitivity of 75% for the detection of primary tumours. In contrast, F-18 FDG PET/CT
is known to be useful in detecting extra-renal metastases with a pooled sensitivity of 91%
(95% CI: 84–96%) since primary tumours with increased F-18 FDG uptake are associated
with metastases [7]. In our study, F-18 FDG and C-11 MET PET/CT detected extra-renal
metastases in all 10 patients (25%). For lymph nodes (n = 3) and lung metastases (n = 7),
both PET/CT modalities played no additional role compared with contrast-enhanced CT.
However, all bone metastases (n = 3) were detected on F-18 FDG and C-11 MET PET/CT
but were negative or equivocal on conventional imaging, including whole-body bone
scintigraphy (WBBS). This was likely attributable to the finding that typical osteolytic bone
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metastases in RCC might not be well-detected on WBBS [46,47]. Further studies with a
larger sample of metastatic lesions are needed to validate the value of F-18 FDG or C-11
MET PET/CT in detecting metastases.
While both F-18 FDG and C-11 MET PET/CT were useful in tumour grading, gly-
colytic tumour volume on F-18 FDG PET/CT was also predictive of advanced stages. Since
it is difficult to predict metabolic features in RCCs based on anatomical imaging modalities
or clinical parameters, metabolic PET/CT may play an important role in developing new
drugs targeting metabolic reprogramming in RCCs. Automated detection of tumours has
recently become feasible even at extremely low effective radiation doses (0.11 mSv) using
deep neural networks [48]. Localised imaging of the kidneys could be performed using
an ultralow dose of F-18 FDG or C-11 MET using deep learning algorithms to simulate
full-dose data. If positive uptake by the primary tumour is observed, a standard dose of
radiotracer can be injected, and conventional whole-body imaging can be performed to
evaluate potential extra-renal metastases. This protocol might maximise the usefulness of
metabolic PET/CT by reducing the cost and unnecessary radiation dose to patients whose
primary tumour shows no increase in uptake.
The present study has some limitations. First, various subtypes of RCC, such as chro-
mophobe RCC and papillary RCC, were included in addition to clear cell RCC. However,
the number of patients was not sufficient to perform subgroup analysis according to the cell
type. Second, survival analysis could not be performed, as enough time had not elapsed
since the commencement of the study. Survival analysis in the future will help clarify the
prognostic role of metabolic PET/CT in RCC. Finally, given the excellent clinical outcomes,
patients with clinical stage I tumours were not included in this study.
4. Materials and Method
4.1. Study Subjects
This prospective study included patients with suspected RCC classified as clinical
stage II or higher on preoperative CT. Altogether, 41 patients underwent F-18 FDG and C-11
MET PET/CT staging between September 2016 and September 2018. The mean interval
between F-18 FDG and C-11 MET PET/CT scans was 1.6 ± 3.2 days (range: 0–14 days).
In addition, all patients underwent conventional imaging, including abdominal CT, chest
CT, and WBBS for conventional initial staging work-up. Thirty-nine patients underwent
radical nephrectomy shortly after imaging (median, 5 days; range, 1–23 days), and the
remaining two patients underwent biopsy alone. For distant metastases, a biopsy was
performed when there was a single lesion or when the lesion was noted at an unexpected
location for RCC metastasis. No prior treatment was performed before imaging in any
of the patients. Among the 41 patients, one patient was diagnosed with a perivascular
epithelioid cell tumour and was thus excluded from the analysis. The remaining 40 patients
with confirmed RCC were included in this study. Clinical parameters such as sex, age,
and histopathological features, including tumour size, histological subtype, and Fuhrman
nuclear grade, were assessed. The Fuhrman grade system was based on a four-point
scale from 1 (best prognosis) to 4 (worst prognosis) [49]. Pathological tumour staging was
performed according to the 2017 TNM criteria of the AJCC [50]. The present prospective
study was approved by the Institutional Review Board of the Yonsei University Health
System (project number: 1-2016-0032), and informed consent was obtained from all patients.
4.2. PET/CT Imaging Protocol
All patients fasted for at least 6 h before being injected with C-11 MET. PET/CT
imaging was performed using a PET/CT scanner (Discovery 710, GE Medical Systems,
Milwaukee, USA). Twenty minutes after intravenous injection of 370–555 MBq (10–15 mCi)
of C-11 MET, a low-dose CT scan (tube voltage, 120 kV; tube current, auto mA) was per-
formed for attenuation correction and precise anatomical localisation. PET emission scans
from the cerebellum to the proximal thigh were acquired for 2 min per bed position in
a three-dimensional mode for approximately 20 min. The acquired images were recon-
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structed with an iterative reconstruction algorithm (VUE point FX-SharpIR, iteration: 2,
subset: 16, filter cut off: 5 mm) using CT images for attenuation correction.
For the F-18 FDG PET/CT scan, patients were instructed to fast for at least 6 h, and
blood glucose levels ≤ 140 mg/dL were ensured before the injection of 5.5 MBq of F-18
FDG per kg body weight. PET/CT images were acquired using the same PET/CT scanner
as the corresponding CT transmission scan protocol for attenuation correction. An emission
scan was acquired from the cerebellum to the proximal thigh for 2 min per bed position.
The same attenuation correction and image reconstruction protocols were used for the F-18
FDG and C-11 MET images.
4.3. PET/CT Image Analysis
C-11 MET and F-18 FDG PET/CT images were registered on contrast-enhanced CT or
magnetic resonance (MR) images using imaging software (MIM 6.5; MIM Software Inc.).
We used automatic registration provided by the software with manual modification. For
the measurement of the standardised uptake value (SUV), a spherical volume of interest
(VOI) was drawn over the tumour, and the maximum SUV (SUVmax) was calculated using
the following formula: (decay-corrected activity (kBq)/tissue volume (mL))/(injected
F-18 FDG or C-11 MET activity (kBq)/body mass (g)). CT or MR images were used as
frequently as possible to avoid activity in the renal calyces, pelvis, and upper ureter on
F-18 FDG PET/CT images. MTV was defined as the total tumour volume above an SUV
cut-off corresponding to the 97.5th percentile of the contralateral kidney (mean SUV of the
contralateral kidney + two standard deviations of the contralateral kidney) in the VOI on
both F-18 FDG PET/CT and C-11 MET PET/CT.
The degree of F-18 FDG and C-11 MET uptake in the primary tumour was evaluated
visually by two experienced nuclear medicine physicians blinded to the patients’ clinical
information. Uptake was considered positive if it was similar to or higher than that of
the contralateral kidney cortex. Uptake in a lesion similar to or higher than the uptake in
the primary tumour was regarded as distant metastasis. Well-known diagnostic pitfalls
related to physiological uptake or benign lesions were considered. Interpreters performed
visual analysis independently and reached a consensus after reviewing disagreement
cases together.
4.4. Statistical Analysis
For statistical analyses, patients were classified into two groups according to the TNM
staging: limited-stage (stages I and II) and advanced-stage (stages III and IV). Fuhrman
grade 1 and grade 2 tumours were considered low-grade tumours, and Fuhrman grade 3
and grade 4 tumours were considered high-grade tumours. Simple and stepwise logistic
regression analyses were used to predict advanced-stage disease. Variables for logistic
regression analyses included sex, age at diagnosis, tumour size, metabolic parameters
(SUVmax, MTV) measured on F-18 FDG PET/CT and C-11 MET PET/CT, and Fuhrman
grade. ROC analysis was used to determine the optimal cut-off value of SUVmax and MTV
for predicting advanced-stage disease using the Euclidean distance. Correlation analyses
were performed among the SUVmax values of primary tumours on F-18 FDG and C-11
MET PET/CT, tumour size, and Fuhrman grade. The Mann–Whitney U-test was used
to compare the SUVmax of F-18 FDG and C-11 MET according to Fuhrman’s grade. ROC
analysis was performed to calculate the AUC of F-18 FDG SUVmax and the AUC of C-11
MET SUVmax for predicting high-grade tumours. The differences between the areas under
the two dependent ROC curves were compared using the Delong method. The McNemar
test was performed to compare F-18 FDG and C-11 MET uptake of the primary tumours
on visual analysis. Inter-observer agreement of visual analysis between two interpreters
was calculated. Statistical analyses were performed using IBM SPSS Statistics (version 26.0;
IBM Corp., Armonk, NY, USA) or MedCalc Statistical Software (version 19.2.6; MedCalc
Software Ltd, Ostend, Belgium). For all tests, two-sided p-values < 0.05, were considered
statistically significant.
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5. Conclusions
Both F-18 FDG and C-11 MET PET/CT showed variable uptake in RCCs and were
useful in predicting tumours with high Fuhrman grades. In particular, high glycolytic
volume on F-18 FDG PET/CT was predictive of advanced-stage diseases. The unique
metabolic features of PET/CT may play an important role in developing new drugs
targeting metabolic reprogramming in RCC.
Supplementary Materials: The following are available online https://www.mdpi.com/article/10.3
390/cancers13102381/s1. Table S1: Characteristics of individual patients.
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